Monopar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 10
- Market Cap
- $8.4M
- Introduction
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
ALXN1840 Shows Promising Long-Term Efficacy and Safety for Wilson Disease at EASL 2025
Monopar Therapeutics presented late-breaker data at EASL 2025 showing sustained clinical improvements in Wilson disease patients treated with ALXN1840 (tiomolybdate choline) over a median treatment duration of 2.63 years.
Monopar Therapeutics Advances Wilson Disease and Radiopharmaceutical Programs
Monopar Therapeutics in-licensed ALXN-1840 from Alexion for Wilson disease, planning regulatory discussions with the FDA focusing on patients with severe symptoms.
Monopar Acquires Late-Stage Wilson Disease Drug Candidate ALXN-1840 from Alexion, AstraZeneca Rare Disease
Monopar Therapeutics has acquired ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease, taking over global development and commercialization.